Predicting Response to Radiotherapy in Breast Cancer-Induced Bone Pain: Relationship Between Pain and Serum Cytokine Expression Levels After Radiotherapy

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2022 Nov 17

PMID 36394055

Authors

Yaling Lou

Henbin Cao

Ronghua Wang

Yu Chen

Haibing Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Breast cancer is the second leading cause of cancer-associated death in women. Herein, we explored the associations of cytokines, pain, and bone metastasis between patients before and after radiotherapy in breast cancer with bone metastasis. The pain caused by metastasis was effectively relieved by external radiation therapy. However, the underlying mechanisms remain unknown.

Methods And Results: In this case-controlled study, we enrolled healthy individuals (n = 10) and bone metastatic cancer patients (n = 30). Peripheral venous blood samples were collected from healthy controls, and one week before and after radiotherapy, the peripheral venous blood and clinical characteristics of cancer patients were collected. We analyzed the blood cytokine profile, quality of life (QOL), and pain score of patients pre- and post-radiotherapy to explore the possible causes of pain relief. Both the pain score and QOL significantly improved after radiotherapy. The serum cytokine profiles of patients were significantly different before radiotherapy than after. Meanwhile, only three cytokines differed between post-radiotherapy and healthy controls. We believe radiotherapy stimulated local immune storms in bone tissue and promoted significant changes in cytokines pre- and post-radiotherapy. Therefore, the bone microenvironment of early breast cancer patients with bone metastasis pain can be restored after radiotherapy. Restoring a healthy bone environment can not only relieve the pain but also improve the patient's QOL.

Conclusion: Tumor cells can effectively activate immune cells in the bone microenvironment through direct interaction, releasing many factors and promoting bone metastasis. Early local radiotherapy of bone metastases can restore the microenvironment and improve the QOL and prognosis of patients, thereby comprehending a novel target for prevention, treatment, and therapy of bone metastases.

References

Rosendahl A, Bjorner S, Rodstrom M, Jirstrom K, Borgquist S, Ingvar C . Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. Front Oncol. 2021; 11:626058. PMC: 7986849. DOI: 10.3389/fonc.2021.626058. View

Brook N, Brook E, Dharmarajan A, Dass C, Chan A . Breast cancer bone metastases: pathogenesis and therapeutic targets. Int J Biochem Cell Biol. 2018; 96:63-78. DOI: 10.1016/j.biocel.2018.01.003. View

Koukourakis I, Koukourakis M . Combining the past and present to advance immuno-radiotherapy of cancer. Int Rev Immunol. 2021; 42(1):26-42. DOI: 10.1080/08830185.2021.1974020. View

Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel R . Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011; 17(11):1473-80. DOI: 10.1038/nm.2489. View

Pulido C, Vendrell I, Ferreira A, Casimiro S, Mansinho A, Alho I . Bone metastasis risk factors in breast cancer. Ecancermedicalscience. 2017; 11:715. PMC: 5295847. DOI: 10.3332/ecancer.2017.715. View

Faris A, Exposito J, Martinez-Unica A, Arrebola J, Perez-Carrascosa F, Guerrero R . The efficacy of three-dimensional conformal radiation therapy on pain and quality of life in patients with painful bone metastases: a prospective study. Croat Med J. 2020; 61(3):215-222. PMC: 7358686. View

Irshad I, Varamini P . Different Targeting Strategies for Treating Breast Cancer Bone Metastases. Curr Pharm Des. 2018; 24(28):3320-3331. DOI: 10.2174/1381612824666180619165728. View

Jensen A, Jacobsen J, Norgaard M, Yong M, Fryzek J, Sorensen H . Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011; 11:29. PMC: 3037922. DOI: 10.1186/1471-2407-11-29. View

Er P, Qian D, Zhang W, Zhang B, Wei H, Zhang T . The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy. Aging (Albany NY). 2020; 12(8):6586-6599. PMC: 7202496. DOI: 10.18632/aging.102993. View

10.

Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinsky J . Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021; 13(602). PMC: 8449934. DOI: 10.1126/scitranslmed.abb3631. View

11.

Cook G, Azad G, Goh V . Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. J Nucl Med. 2016; 57 Suppl 1:27S-33S. DOI: 10.2967/jnumed.115.157867. View

12.

Purushotham A, Shamil E, Cariati M, Agbaje O, Muhidin A, Gillett C . Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship. Eur J Cancer. 2014; 50(10):1697-1705. DOI: 10.1016/j.ejca.2014.04.002. View

13.

Yardley D . Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press). 2016; 8:73-82. PMC: 4861000. DOI: 10.2147/BCTT.S97963. View

14.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

15.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

16.

Farhood B, Khodamoradi E, Hoseini-Ghahfarokhi M, Motevaseli E, Mirtavoos-Mahyari H, Musa A . TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury. Pharmacol Res. 2020; 155:104745. DOI: 10.1016/j.phrs.2020.104745. View

17.

Rich S, Chow R, Raman S, Zeng K, Lutz S, Lam H . Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018; 126(3):547-557. DOI: 10.1016/j.radonc.2018.01.003. View

18.

MacLeod K, Laird B, Carragher N, Hoskin P, Fallon M, Sande T . Predicting Response to Radiotherapy in Cancer-Induced Bone Pain: Cytokines as a Potential Biomarker?. Clin Oncol (R Coll Radiol). 2020; 32(10):e203-e208. DOI: 10.1016/j.clon.2020.03.010. View

19.

Lyu X, Luo B . Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study. Cancer Med. 2021; 10(22):8114-8126. PMC: 8607243. DOI: 10.1002/cam4.4326. View

20.

Yao M, Brummer G, Acevedo D, Cheng N . Cytokine Regulation of Metastasis and Tumorigenicity. Adv Cancer Res. 2016; 132:265-367. DOI: 10.1016/bs.acr.2016.05.005. View